The effect of sodium-glucose transport protein 2 inhibitor and fibrate therapies, alone and in combination, on the serum uric acid concentration in hyperuricaemic people with type 2 diabetes

Timothy Davis0 个研究点目标入组 10 人开始时间: 2021年6月29日最近更新: 2021年7月5日

适应症

试验速览

暂无简介。

•Type 2 diabetes diagnosed at least 3 months previously and treated with stable oral blood glucose lowering therapies
•Age between 18 and 70 years apart from women of child-bearing age who will be excluded.
•Body mass index between 20 and 40 kg/m²
•Glycated haemoglobin >6.5% and <9.0%
•Hyperuricaemia (serum uric acid above the upper limit of the laboratory reference range i.e. greater than to equal to 0.42 mmol/L)
•No current therapy with either an SGLT2i or a fibrate, or allopurinol or febuxostat
•No history of intolerance or adverse effects with past use of an SGLT2i or a fibrate
•No contraindications to SGLT2i or fibrate use including renal impairment (eGFR <45 mL/min), past history of recurrent genitourinary infections and/or symptomatic postural hypotension
•Stable doses of any medications (such as aspirin and thiazide diuretics) known to influence serum uric acid concentrations
•Stable alcohol intake of <3 standard drinks/day
•No recent history of smoking
•No significant co-morbidity such as cancer or mental health issues that would affect the ability to follow a normal lifestyle and take regular medications including allocated
•Ability to provide written informed consent and to attend all scheduled study assessments

•Type 1 or other non-Type 2 forms of diabetes
•Diagnosed within the last 3 months
•Recent changes in oral blood glucose lowering therapies
•Age lower than 18 years and greater than 70 years
•Women of child-bearing age
•Body mass index below 20 and greater than40 kg/m²
•Glycated haemoglobin <6.5% and >9.0%
•Normal serum uric acid (below the upper limit of the laboratory reference range or <0.42 mmol/L)
•Current therapy with either an SGLT2i or a fibrate, or allopurinol or febuxostat
•A history of intolerance or adverse effects with past use of an SGLT2i or a fibrate
•Contraindications to SGLT2i or fibrate use including renal impairment (eGFR <45 mL/min), past history of recurrent genitourinary infections and/or symptomatic postural hypotension
•Unstable doses of any medications (such as aspirin and thiazide diuretics) known to influence serum uric acid concentrations
•Alcohol intake of >3 standard drinks/day
•Recent smoking
•Significant co-morbidity such as cancer or mental health issues that would affect the ability to follow a normal lifestyle and take regular medications including allocated
•Inability to provide written informed consent and to attend all scheduled study assessments

发起方

Timothy Davis